Rare Variant Genetics and Dilated Cardiomyopathy Severity: The DCM Precision Medicine Study.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
12 09 2023
Historique:
pmc-release: 12 09 2024
medline: 13 9 2023
pubmed: 29 8 2023
entrez: 29 8 2023
Statut: ppublish

Résumé

Dilated cardiomyopathy (DCM) can lead to advanced disease, defined herein as necessitating a durable left ventricular assist device or a heart transplant (LVAD/HT). DCM is known to have a genetic basis, but the association of rare variant genetics with advanced DCM has not been studied. We analyzed clinical and genetic sequence data from patients enrolled between 2016 and 2021 in the US multisite DCM Precision Medicine Study, which was a geographically diverse, multiracial, multiethnic cohort. Clinical evaluation included standardized patient interview and medical record query forms. DCM severity was classified into 3 groups: patients with advanced disease with LVAD/HT; patients with an implantable cardioverter defibrillator (ICD) only; or patients with no ICD or LVAD/HT. Rare variants in 36 DCM genes were classified as pathogenic or likely pathogenic or variants of uncertain significance. Confounding factors we considered included demographic characteristics, lifestyle factors, access to care, DCM duration, and comorbidities. Crude and adjusted associations between DCM severity and rare variant genetic findings were assessed using multinomial models with generalized logit link. Patients' mean (SD) age was 51.9 (13.6) years; 42% were of African ancestry, 56% were of European ancestry, and 44% were female. Of 1198 patients, 347 had LVAD/HT, 511 had an ICD, and 340 had no LVAD/HT or ICD. The percentage of patients with pathogenic or likely pathogenic variants was 26.2%, 15.9%, and 15.0% for those with LVAD/HT, ICD only, or neither, respectively. After controlling for sociodemographic characteristics and comorbidities, patients with DCM with LVAD/HT were more likely than those without LVAD/HT or ICD to have DCM-related pathogenic or likely pathogenic rare variants (odds ratio, 2.3 [95% CI, 1.5-3.6]). The association did not differ by ancestry. Rare variant genetic findings were similar between patients with DCM with an ICD and those without LVAD/HT or ICD. Advanced DCM was associated with higher odds of rare variants in DCM genes adjudicated as pathogenic or likely pathogenic, compared with individuals with less severe DCM. This finding may help assess the risk of outcomes in management of patients with DCM and their at-risk family members. URL: https://www. gov; Unique identifier: NCT03037632.

Sections du résumé

BACKGROUND
Dilated cardiomyopathy (DCM) can lead to advanced disease, defined herein as necessitating a durable left ventricular assist device or a heart transplant (LVAD/HT). DCM is known to have a genetic basis, but the association of rare variant genetics with advanced DCM has not been studied.
METHODS
We analyzed clinical and genetic sequence data from patients enrolled between 2016 and 2021 in the US multisite DCM Precision Medicine Study, which was a geographically diverse, multiracial, multiethnic cohort. Clinical evaluation included standardized patient interview and medical record query forms. DCM severity was classified into 3 groups: patients with advanced disease with LVAD/HT; patients with an implantable cardioverter defibrillator (ICD) only; or patients with no ICD or LVAD/HT. Rare variants in 36 DCM genes were classified as pathogenic or likely pathogenic or variants of uncertain significance. Confounding factors we considered included demographic characteristics, lifestyle factors, access to care, DCM duration, and comorbidities. Crude and adjusted associations between DCM severity and rare variant genetic findings were assessed using multinomial models with generalized logit link.
RESULTS
Patients' mean (SD) age was 51.9 (13.6) years; 42% were of African ancestry, 56% were of European ancestry, and 44% were female. Of 1198 patients, 347 had LVAD/HT, 511 had an ICD, and 340 had no LVAD/HT or ICD. The percentage of patients with pathogenic or likely pathogenic variants was 26.2%, 15.9%, and 15.0% for those with LVAD/HT, ICD only, or neither, respectively. After controlling for sociodemographic characteristics and comorbidities, patients with DCM with LVAD/HT were more likely than those without LVAD/HT or ICD to have DCM-related pathogenic or likely pathogenic rare variants (odds ratio, 2.3 [95% CI, 1.5-3.6]). The association did not differ by ancestry. Rare variant genetic findings were similar between patients with DCM with an ICD and those without LVAD/HT or ICD.
CONCLUSIONS
Advanced DCM was associated with higher odds of rare variants in DCM genes adjudicated as pathogenic or likely pathogenic, compared with individuals with less severe DCM. This finding may help assess the risk of outcomes in management of patients with DCM and their at-risk family members.
REGISTRATION
URL: https://www.
CLINICALTRIALS
gov; Unique identifier: NCT03037632.

Identifiants

pubmed: 37641966
doi: 10.1161/CIRCULATIONAHA.123.064847
pmc: PMC10530109
mid: NIHMS1923894
doi:

Banques de données

ClinicalTrials.gov
['NCT03037632']

Types de publication

Clinical Study Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

872-881

Subventions

Organisme : NHLBI NIH HHS
ID : K08 HL133491
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128857
Pays : United States

Références

Circ Cardiovasc Genet. 2017 Dec;10(6):
pubmed: 29237686
Circ Genom Precis Med. 2020 Aug;13(4):e000067
pubmed: 32698598
Circ Heart Fail. 2018 Nov;11(11):e005220
pubmed: 30571196
J Card Fail. 2018 May;24(5):281-302
pubmed: 29567486
J Am Coll Cardiol. 2021 Oct 26;78(17):1682-1699
pubmed: 34674813
J Heart Lung Transplant. 2022 Sep;41(9):1218-1227
pubmed: 35581137
Circulation. 1997 Sep 16;96(6):1863-73
pubmed: 9323074
ESC Heart Fail. 2021 Feb;8(1):95-105
pubmed: 33179448
Am J Hum Genet. 2022 Dec 1;109(12):2110-2125
pubmed: 36400022
J Heart Lung Transplant. 2016 Aug;35(8):953-61
pubmed: 27080415
N Engl J Med. 1999 Feb 25;340(8):609-16
pubmed: 10029645
PLoS One. 2017 Dec 18;12(12):e0189489
pubmed: 29253866
Circulation. 2022 May 3;145(18):e895-e1032
pubmed: 35363499
JAMA. 2021 Aug 17;326(7):621-627
pubmed: 34402850
Curr Cardiol Rep. 2022 Sep;24(9):1077-1084
pubmed: 35900642
JAMA. 2022 Feb 1;327(5):454-463
pubmed: 35103767
Circ Heart Fail. 2023 Jan;16(1):e009745
pubmed: 36259388
Circ Heart Fail. 2022 May;15(5):e008877
pubmed: 35240856
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Genet Med. 2021 Jun;23(6):1004-1007
pubmed: 33649579
Genet Med. 2021 Nov;23(11):2186-2193
pubmed: 34194005
J Heart Lung Transplant. 2016 May;35(5):625-35
pubmed: 26899768
Circulation. 2023 Apr 25;147(17):1281-1290
pubmed: 36938756
Circ Heart Fail. 2020 Oct;13(10):e006832
pubmed: 32964742
N Engl J Med. 2009 Mar 19;360(12):1179-90
pubmed: 19297571
Rev Port Cardiol (Engl Ed). 2019 Jun;38(6):441-447
pubmed: 31303467
Circ Genom Precis Med. 2020 Apr;13(2):e002480
pubmed: 32160020
J Am Coll Cardiol. 2022 Oct 11;80(15):1447-1461
pubmed: 36007715
Eur J Heart Fail. 2017 Apr;19(4):512-521
pubmed: 27813223
Circ Heart Fail. 2018 Aug;11(8):e005008
pubmed: 30021796
Genome Res. 2009 Sep;19(9):1655-64
pubmed: 19648217
Circ Heart Fail. 2022 Aug;15(8):e009352
pubmed: 35543125
JAMA. 2023 Aug 1;330(5):432-441
pubmed: 37526719
Circ Genom Precis Med. 2021 Aug;14(4):e000084
pubmed: 34304578
Circ Cardiovasc Qual Outcomes. 2021 Feb;14(2):e007868
pubmed: 33567860

Auteurs

Mark Hofmeyer (M)

MedStar Health Research Institute, Medstar Washington Hospital Center, Washington, DC (M.H.).

Garrie J Haas (GJ)

The Davis Heart and Lung Research Institute (G.J.H., E.J., J.C., D.D.K., H.N., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.
Divisions of Cardiovascular Medicine (G.J.H., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.
Cardiology Division, Tufts Medical Center and Tufts University School of Medicine, Boston, MA (G.S.H.).

Elizabeth Jordan (E)

The Davis Heart and Lung Research Institute (G.J.H., E.J., J.C., D.D.K., H.N., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.
Human Genetics (E.J., J.C., D.D.K., H.N., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.

Jinwen Cao (J)

The Davis Heart and Lung Research Institute (G.J.H., E.J., J.C., D.D.K., H.N., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.
Human Genetics (E.J., J.C., D.D.K., H.N., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.

Evan Kransdorf (E)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (E.K.).

Gregory A Ewald (GA)

Washington University, St Louis, MO (G.A.E.).

Alanna A Morris (AA)

Emory University School of Medicine, Atlanta, GA (A.A.M.).

Anjali Owens (A)

Center for Inherited Cardiovascular Disease, Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.O.).

Brian Lowes (B)

University of Nebraska Medical Center, Omaha (B.L., D.S.).

Douglas Stoller (D)

University of Nebraska Medical Center, Omaha (B.L., D.S.).

W H Wilson Tang (WH)

Heart Vascular and Thoracic Institute, Cleveland Clinic, OH (W.H.W.T.).

Sonia Garg (S)

University of Texas Southwestern Medical Center, Dallas (S.G.).

Barry H Trachtenberg (BH)

Houston Methodist DeBakey Heart and Vascular Center, J.C. Walter Jr Transplant Center, TX (B.H.T.).

Palak Shah (P)

Inova Heart and Vascular Institute, Falls Church, VA (P.S.).

Salpy V Pamboukian (SV)

University of Alabama, Birmingham, during study conduct; current affiliation, University of Washington, Seattle (S.V.P.).

Nancy K Sweitzer (NK)

Sarver Heart Center, University of Arizona, Tucson, during study conduct; current affiliation, Washington University, St Louis, MO (N.K.S.).

Matthew T Wheeler (MT)

Division of Cardiovascular Medicine, Stanford University School of Medicine, CA (M.T.W.).

Jane E Wilcox (JE)

Northwestern University Feinberg School of Medicine, Chicago, IL (J.E.W.).

Stuart Katz (S)

New York University Langone Medical Center, New York (S.K., S.P.).

Stephen Pan (S)

New York University Langone Medical Center, New York (S.K., S.P.).
current affiliation, Department of Cardiology, Westchester Medical Center & New York Medical College, Valhalla, NY (S.P.).

Javier Jimenez (J)

Miami Cardiac & Vascular Institute, Baptist Health South, FL (J.J.).

Frank Smart (F)

Louisiana State University Health Sciences Center, New Orleans (F.S.).

Jessica Wang (J)

University of California Los Angeles Medical Center (J.W.).

Stephen S Gottlieb (SS)

University of Maryland School of Medicine, Baltimore (S.S.G.).

Daniel P Judge (DP)

Medical University of South Carolina, Charleston (D.P.J.).

Charles K Moore (CK)

University of Mississippi Medical Center, Jackson (C.K.M.).

Daniel D Kinnamon (DD)

The Davis Heart and Lung Research Institute (G.J.H., E.J., J.C., D.D.K., H.N., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.
Human Genetics (E.J., J.C., D.D.K., H.N., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.

Hanyu Ni (H)

The Davis Heart and Lung Research Institute (G.J.H., E.J., J.C., D.D.K., H.N., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.
Human Genetics (E.J., J.C., D.D.K., H.N., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.

Ray E Hershberger (RE)

The Davis Heart and Lung Research Institute (G.J.H., E.J., J.C., D.D.K., H.N., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.
Divisions of Cardiovascular Medicine (G.J.H., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.
Human Genetics (E.J., J.C., D.D.K., H.N., R.E.H.), Department of Internal Medicine, The Ohio State University, Columbus.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH